Gataparsen

Gataparsen
Clinical data
Other namesLY2181308
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Gataparsen (development code LY2181308) is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.[1]

It being investigated for a number of different cancers.[2]

It is targeted at survivin which prevents cells dying.[3]

Clinical trials

It has completed a phase II trial for acute myeloid leukemia.[4]

A phase II trial for non-small cell lung cancer has started.[5]

A phase II trial for hormone-refractory prostate cancer will run until early 2012.[6]

References

  1. ↑ Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, et al. (August 2011). "Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors". Cancer Chemotherapy and Pharmacology. 68 (2): 505–11. doi:10.1007/s00280-010-1506-7. PMID 21079959.
  2. ↑ "Search of: LY2181308". ClinicalTrials.gov.
  3. ↑ "Cancer". Isis Pharmaceuticals. Archived from the original on 2009-10-10. Retrieved 2019-08-31.
  4. ↑ "A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia". ClinicalTrials.gov.
  5. ↑ "Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer". ClinicalTrials.gov.
  6. ↑ "A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer". ClinicalTrials.gov.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.